Elicio Therapeutics, Inc. — Investor Relations & Filings

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for cancer treatment. The company utilizes its proprietary Amphiphile (AMP) platform to deliver vaccines, immunomodulators, and adjuvants directly to the lymph nodes. This targeted-delivery approach is designed to bind therapeutic agents to albumin, a protein in the bloodstream, facilitating their transport to the immune system's central hubs. The goal is to generate a robust and durable immune response by activating and amplifying cancer-fighting T cells. Elicio's pipeline focuses on aggressive cancers, with a lead program in pancreatic ductal adenocarcinoma (PDAC).